Ajovy market forecast points to faster growth in migraine prevention

The Business Research Company says the Ajovy market is set to expand through 2035 as migraine diagnoses rise, preventive treatment gains ground and biologic therapies become more accepted. North America led the market in 2025, while Asia-Pacific is projected to grow the fastest.

Why it matters: - Ajovy sits in a market tied to a large and growing migraine patient population. - The forecast signals stronger demand for preventive migraine treatments and biologic therapies. - The market outlook matters for neurology care, reimbursement decisions and patient access to long-acting injectable options.

What happened: - The Business Research Company published a new report on the global Ajovy market, covering market size, trends and forecasts for 2026-2035. - The report says the Ajovy market is gaining attention as migraine treatment evolves and unmet needs remain significant. - The report includes a free sample at more information. - The full report is available here.

The details: - Ajovy is a monoclonal antibody used to prevent chronic and episodic migraines in adults. - Ajovy works by blocking the calcitonin gene-related peptide, or CGRP, receptor. - The report points to several past growth drivers, including unmet need in migraine treatment, approval and adoption of CGRP biologics, changing neurologist prescribing behavior, dissatisfaction with oral medications and more specialty neurology care. - The report expects further growth from rising diagnoses of episodic migraines, broader preventive treatment guidelines, higher acceptance of biologic therapies, better reimbursement and more patient education. - The report highlights several trends, including increased use of CGRP monoclonal antibodies, a shift toward preventive treatment, preference for long-acting injectables, more self-administration and wider recognition of migraine as a chronic condition. - Migraine prevalence is a key demand driver because more patients are seeking treatment options that reduce attack frequency and severity. - The House of Commons Library reported in March 2024 that about 10 million people in the UK experience migraines. - The Migraine Trust says more than 1 million people in the UK have chronic migraines, defined as symptoms on at least 15 days per month. - North America accounted for the largest share of the Ajovy market in 2025. - Asia-Pacific is projected to be the fastest-growing regional market during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 edition of the report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis.

Between the lines: - The report frames Ajovy as part of a broader shift away from acute migraine care and toward prevention. - Faster growth in Asia-Pacific suggests expanding access and awareness could become as important as product adoption in established markets. - The emphasis on self-administration and long-acting injectables suggests convenience remains a major factor in treatment choice.

What's next: - The report points to continued market expansion through 2035 if preventive prescribing, reimbursement and patient education keep improving. - Regional growth will likely depend on how quickly healthcare systems expand access to biologic migraine therapies. - More adoption of self-administered injectables could widen use beyond specialty care settings.

The bottom line: - Ajovy’s market outlook is being lifted by rising migraine prevalence, stronger acceptance of CGRP therapies and a broader shift toward prevention.